Ji Wenxiao, Zhuang Xinguo, Jiang Wen G, Martin Tracey A
Division of Cancer and Genetics, Cardiff China Medical Research Collaborative, University School of Medicine, Cardiff, United Kingdom.
Center for Precision Medicine, The First Affiliated Hospital of Xiamen University, School of Medicine, Xiamen University, Xiamen, China.
Front Oncol. 2025 Jul 4;15:1596460. doi: 10.3389/fonc.2025.1596460. eCollection 2025.
Claudin (CLDN) family proteins are key components of tight junctions in epithelial and endothelial cells, crucial for controlling paracellular permeability and cell-cell adhesion. Aberrant CLDNS expression is frequently observed in cancers and has been linked to tumor progression, invasion, and metastasis. Recent years have seen a rapid advance in exploring the role played by this protein family in cancer and cancer metastasis, and even chemotherapy response. This article provides a comprehensive overview of the roles of CLDNs in solid tumors, highlighting how specific CLDN members function as oncogenic drivers or tumor suppressors in different cancer types. We also discuss the potential of CLDNs as biomarkers for prognosis and therapeutic targets (e.g. CLDN18.2-targeted immunotherapy). The inclusion of updated literature (particularly post-2020) and bioinformatic analyses (TCGA/GEPIA) reveal emerging trends. Finally, we summarize common patterns of CLDN dysregulation across cancers and outline future research directions, including pan-cancer CLDN analyses and translational strategies.
紧密连接蛋白(CLDN)家族蛋白是上皮细胞和内皮细胞中紧密连接的关键组成部分,对控制细胞旁通透性和细胞间黏附至关重要。在癌症中经常观察到CLDNs表达异常,并且其与肿瘤进展、侵袭和转移有关。近年来,在探索该蛋白家族在癌症、癌症转移甚至化疗反应中所起的作用方面取得了迅速进展。本文全面概述了CLDNs在实体瘤中的作用,重点介绍了特定CLDN成员在不同癌症类型中作为致癌驱动因子或肿瘤抑制因子的功能。我们还讨论了CLDNs作为预后生物标志物和治疗靶点的潜力(例如靶向CLDN18.2的免疫疗法)。纳入最新文献(特别是2020年以后的)和生物信息学分析(TCGA/GEPIA)揭示了新出现的趋势。最后,我们总结了癌症中CLDN失调的常见模式,并概述了未来的研究方向,包括泛癌CLDN分析和转化策略。